$LSTA

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Lisata Therapeutics (LSTA) said it sued Kuva Labs and Kuva Acquisition Corp. in Delaware Chancery for breach of the merger agreement. Lisata seeks damages for stockholders and a $2 million termination fee. The company also cut about 72% of staff and said its board is evaluating strategic alternatives. Pre-market, LSTA traded at $1.07, up 2.88% on Nasdaq.

Lisata Therapeutics (LSTA) said its merger with Kuva Acquisition Corp was terminated and it has sued Kuva in Delaware Chancery for breach, seeking damages including a $2 million termination fee. The board is reviewing strategic options. To cut costs, it reduced its workforce by 72%. LSTA stock closed at $1.04.

Lisata Therapeutics (NASDAQ:LSTA) said it filed suit in Delaware Chancery after Kuva Labs and Kuva Acquisition Corp terminated their March 6, 2026 merger agreement. Lisata alleges breach and seeks damages plus a $2 million termination fee. It also cut full-time roles by about 72% to preserve cash while evaluating strategic alternatives. Lead candidate is certepetide.

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000320017 NASDAQ 0000320017 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 3, 2026 Date of Report (date of earliest event re

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0000320017 NASDAQ 0000320017 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 24, 2026 Date of Report (date of earliest event rep

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0000320017 NASDAQ 0000320017 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 16, 2026 Date of Report (date of earliest event rep

Lisata Therapeutics agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus contingent value rights up to $3.00 per share tied to certepetide drug milestones. Kuva’s tender offer began June 10 and runs until July 10, 2026. Lisata’s board unanimously recommended tendering; deal closes in Q3 2026 and Lisata will be delisted.

U.S. stocks fell Wednesday after hotter-than-expected CPI revived concerns about Federal Reserve policy. The Dow closed down 954 points (1.9%) at 49,919, the S&P 500 fell 1.6% to 7,267, and the Nasdaq dropped 2% to 25,170. May inflation rose to 4.2% y/y and core to 2.9%, with energy and Middle East tensions cited as drivers.

U.S. stocks fell Wednesday after May inflation came in hotter than expected, reviving concerns the Federal Reserve may keep rates higher for longer. The Dow fell 954 points (1.9%) to 49,919, the S&P 500 dropped 1.6% to 7,267, and the Nasdaq slid 2% to 25,170. Annual CPI rose to 4.2% and core to 2.9%, with energy and labor-intensive services cited.